HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF); * Age ≥ 18 years; * Phase 1a dose escalation: patients must have histologically or cytologically confirmed malignant solid tumors which are advanced or metastatic, have failed prior standard treatment, and be intolerant or ineligible for standard therapy; * Phase 1b dose expansion: patients must have a histological or cytological diagnosis of Squamous Non-Small Cell Lung Cancer (EGFR H score ≥200 confirmed by central lab) which is advanced or metastatic, have failed prior standard treatment, and be intolerant or ineligible for standard therapy; * Measurable disease according to RECIST Version 1.1; * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; * Expected survival 12 weeks; * Adequate organ function; Exclusion Criteria: * Systemic anti-cancer treatment or investigational agents in the 28 days prior to the first study dosing; * Patients who still have persistent ≥ grade 2 toxicities from prior therapies; * Active CNS metastasis; * History of any secondary malignancy in the past 5 years; * Active autoimmune disease; * Human immunodeficiency virus (HIV) infection;